Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-DK-18-023

Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/44 Clinical Trial Not Allowed)

Closed on March 21, 2019.

Posted
January 18, 2019
Close date
March 21, 2019
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
2
2 new
Median first-year cost
$297,242
$594,483 in all
Institutions
2
2 contact PIs

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. 21ST CENTURY MEDICINE, INC.1
  2. SILICON KIDNEY, LLC1

Most frequent study sections

  1. Special Emphasis Panel (ZDK1 GRB-M (O2))2
2 awards under RFA-DK-18-023 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2019A high oxygen capacity cell scaffold for the intravascular bioartifical pancreas (iBAP)1R43DK123775-01Blaha, CharlesSILICON KIDNEY, LLC, CAFirst-year cost $298,388Study section ZDK1
FY2019Development of Novel Storage Method for Highly Viable and Well-Characterized Vitrified Human Islets1R43DK123777-01Fahy, Gregory M21ST CENTURY MEDICINE, INC., CAFirst-year cost $296,095Study section ZDK1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-21-0.3.10. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.

RFA-DK-18-023: Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/44 Clinical Trial Not Allowed) | ConductScience ScienceDex